Literature DB >> 18506915

Strategy for treatment of nonerosive reflux disease in Asia.

Toru Hiyama1, Masaharu Yoshihara, Shinji Tanaka, Ken Haruma, Kazuaki Chayama.   

Abstract

The paper is to review the clinical and pathophysiologic differences between of nonerosive reflux disease (NERD) and reflux esophagitis (RE), and to propose a treatment strategy for NERD, especially for patients in Asia. A Medline search was performed regarding the clinical and pathophysiologic differences between NERD and RE, and treatment of NERD and RE. The characteristics of NERD patients in Asia are as follows: (1) high proportion of female patients, (2) low frequency of hiatal hernia, (3) high frequency of H pylori infection, (4) severe glandular atrophy of the gastric mucosa, and (5) frequent resistance to proton pump inhibitor (PPI) therapy. In Asian NERD patients, exposure of the esophagus to acid is not increased, and esophageal motility is normal. These characteristics are similar to those of patients in Western countries. Our recommended first-choice treatment is administration of PPI in combination with a prokinetic agent. However, at present, because there is limited evidence regarding effective treatments for NERD, it is best to try several different treatment strategies to find the best treatment for each patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506915      PMCID: PMC2712842          DOI: 10.3748/wjg.14.3123

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  57 in total

1.  Site of action of GABA(B) receptor for vagal motor control of the lower esophageal sphincter in ferrets and rats.

Authors:  C M McDermott; T P Abrahams; E Partosoedarso; N Hyland; J Ekstrand; M Monroe; P J Hornby
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

2.  Symptom resolution does not predict healing of erosive oesophagitis in Chinese.

Authors:  Ting Kin Cheung; Wai Man Wong; Nina Y H Wong; Chi Kuen Chan; James Fung; Man Fung Yuen; Annie O O Chan; Teresa S M Tong; Benjamin C Y Wong
Journal:  Digestion       Date:  2007-07-13       Impact factor: 3.216

3.  Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males.

Authors:  Yuichi Sakurai; Masashi Hirayama; Muneaki Hashimoto; Takanori Tanaka; Setsuo Hasegawa; Shin Irie; Kiyoshi Ashida; Yuichiro Kayano; Masato Taguchi; Yukiya Hashimoto
Journal:  Biol Pharm Bull       Date:  2007-12       Impact factor: 2.233

4.  Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis.

Authors:  Justin C Y Wu; Carrian M Y Cheung; Vincent W S Wong; Joseph J Y Sung
Journal:  Clin Gastroenterol Hepatol       Date:  2007-05-04       Impact factor: 11.382

5.  Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.

Authors:  Masaki Miyamoto; Ken Haruma; Keisuke Takeuchi; Masao Kuwabara
Journal:  J Gastroenterol Hepatol       Date:  2007-11-19       Impact factor: 4.029

Review 6.  Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment.

Authors:  Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2007-08-08       Impact factor: 22.682

7.  Effects of rikkunshito on the clinical symptoms and esophageal acid exposure in children with symptomatic gastroesophageal reflux.

Authors:  Hisayoshi Kawahara; Akio Kubota; Toshimichi Hasegawa; Hiroomi Okuyama; Takehisa Ueno; Shinobu Ida; Masahiro Fukuzawa
Journal:  Pediatr Surg Int       Date:  2007-10       Impact factor: 1.827

8.  The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms.

Authors:  Mark Fox; Carole Barr; Suzanne Nolan; Miranda Lomer; Angela Anggiansah; Terry Wong
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03-23       Impact factor: 11.382

9.  Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.

Authors:  Yi-Chia Lee; Jaw-Town Lin; Hsiu-Po Wang; Han-Mo Chiu; Ming-Shiang Wu
Journal:  J Gastroenterol Hepatol       Date:  2007-06-07       Impact factor: 4.029

10.  Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials.

Authors:  Toru Hiyama; Masaharu Yoshihara; Keitaro Matsuo; Hiroaki Kusunoki; Tomoari Kamada; Masanori Ito; Shinji Tanaka; Kazuaki Chayama; Ken Haruma
Journal:  J Gastroenterol Hepatol       Date:  2007-10       Impact factor: 4.029

View more
  20 in total

Review 1.  Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.

Authors:  Li-Hua Ren; Wei-Xu Chen; Li-Juan Qian; Shuo Li; Min Gu; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life.

Authors:  Xiao-Jun Yang; Hong-Mei Jiang; Xiao-Hua Hou; Jun Song
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

3.  Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.

Authors:  Kazunari Tominaga; Ryuichi Iwakiri; Kazuma Fujimoto; Yasuhiro Fujiwara; Mio Tanaka; Yasuyuki Shimoyama; Eiji Umegaki; Kazuhide Higuchi; Motoyasu Kusano; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2011-11-15       Impact factor: 7.527

4.  Gastro-esophageal reflux disease: the recent trend in Japan.

Authors:  Hiroto Miwa; Tadayuki Oshima; Toshihiko Tomita; Yongmin Kim; Kazutoshi Hori; Takayuki Matsumoto
Journal:  Clin J Gastroenterol       Date:  2008-12-02

5.  Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa.

Authors:  Hiroto Miwa; Junichi Koseki; Tadayuki Oshima; Takashi Kondo; Toshihiko Tomita; Jiro Watari; Takayuki Matsumoto; Tomohisa Hattori; Kunitsugu Kubota; Seiichi Iizuka
Journal:  J Gastroenterol       Date:  2009-12-18       Impact factor: 7.527

6.  Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.

Authors:  Xiao-Ping Niu; Bao-Ping Yu; Yun-Dong Wang; Zhen Han; Shao-Fen Liu; Chi-Yi He; Guo-Zheng Zhang; Wan-Chun Wu
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

7.  A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.

Authors:  Kazunari Tominaga; Mototsugu Kato; Hiroshi Takeda; Yasuyuki Shimoyama; Eiji Umegaki; Ryuichi Iwakiri; Kenji Furuta; Koichi Sakurai; Takeo Odaka; Hiroaki Kusunoki; Akihito Nagahara; Katsuhiko Iwakiri; Takahisa Furuta; Kazunari Murakami; Hiroto Miwa; Yoshikazu Kinoshita; Ken Haruma; Shin'ichi Takahashi; Sumio Watanabe; Kazuhide Higuchi; Motoyasu Kusano; Kazuma Fujimoto; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2014-02-18       Impact factor: 7.527

8.  Differences in clinical characteristics between patients with non-erosive reflux disease and erosive esophagitis in Korea.

Authors:  Na Rae Ha; Hang Lak Lee; Oh Young Lee; Byung Chul Yoon; Ho Soon Choi; Joon Soo Hahm; You Hern Ahn; Dong Hee Koh
Journal:  J Korean Med Sci       Date:  2010-08-12       Impact factor: 2.153

9.  Detection of gastroesophageal reflux esophagitis using 2-fluoro-2-deoxy-d-glucose positron emission tomography.

Authors:  Min-Kuei Tsai; Hueisch-Jy Ding; Hsueh-Chou Lai; Kuo-Yang Yen; Chia-Ing Li; Yu-Yi Lin; Kai-Yuan Cheng; Keh-Bin Wang; Chia-Hung Kao
Journal:  ScientificWorldJournal       Date:  2012-07-31

Review 10.  Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application.

Authors:  Kazunari Tominaga; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2013-03-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.